Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth
The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families
It was recognized for its holistic initiatives designed to improve the quality of life and standards of care for patients
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
Subscribe To Our Newsletter & Stay Updated
